INDUSTRY SESSIONS: SATELLITE SYMPOSIA & CONSULT THE EXPERT
Satellite Symposia and Consult the Expert sessions will take place during EULAR 2026. These sessions are governed by the EULAR Code of Practice and are strictly prohibited during official scientific programme hours. All industry sessions require approval by EULAR.
To comply with local and European regulations, particularly regarding prescription rights:
- Participants with a white dot on their EULAR 2026 Congress badge are not permitted to access any industry sessions (Satellite Symposia or Consult the Expert).
- Exhibitor badges are only valid for entry to the sessions they are organising.
Thank you for adhering to these rules.
Note:
- Satellite Symposia and Consult the Expert sessions are intended for Delegates entitled to prescribe or supply Prescription-only Medicines (POM).
- These sessions and their content are independently organised and funded by international pharmaceutical companies, and are separate from EULAR.
INDUSTRY PROGRAMME
See the online Industry Programme
18:30 - 19:45 BST
- AbbVie - At the Crossroads in RA Care: Navigating Treatment Choices
- Alfasigma - Optimising axSpA care: Earlier recognition and better management of disease burden
- Gedeon Richter - Prevention better than treatment: Insights on inflammatory joint disease and osteoporosis
- Johnson & Johnson - Tonight on the EULAR stage: the psoriatic disease spectrum
- MSD - Decoding Immune Fibrotic Cross Talk in Rheumatology: From Mechanisms to Decisions
- UCB and Biogen - The Treat-to-Target Balancing Act in SLE Management: Burden, Benefit and Risk
15:45 – 16:15 BST
- AstraZeneca - Achieving disease control early for patients with SLE: why target the IFN pathway?
- MSD - Early ILD Recognition in SARD/SSc: Drivers of Progression and Workflow Solutions
08:15 - 09:30 (75 mins) | Satellite Symposia |
| 09:30 | Exhibition opens |
09:30 - 10:30 (60 mins) 09:45 - 10:15 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
10:30 - 12:00 (90 mins) | Abstract sessions |
12:00 - 13:30 (90 mins) | Lunch & Poster Viewing and Tours |
13:30 - 14:45 (75 mins) | Scientific sessions |
14:45 - 15:45 (60 mins) 15:00 - 15:30 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
| 15:45 - 17:00 (75 mins) | Scientific sessions |
| 17:00 | Exhibition Closes |
| 17:30 - 18:45 (75 mins) | Satellite Symposia |
12:15 – 13:30 BST
- Alfasigma - Optimising RA treatment in 2026: applying lessons from two decades of therapeutic progress
- AstraZeneca - Time matters: why rapid disease control is the foundation to preventing organ damage in SLE
- Boehringer Ingelheim - One patient, one team: tackling autoimmune ILD cases with a rheumatologist, a radiologist and a pulmonologist
- Bristol-Myers Squibb - Autoimmune Disease Trajectories: CAR T Cell Therapy and Perspectives on Immune Reset in SLE and SSc
- Eli Lilly - When Good Treatment Isn’t Enough: Evolving the Standard of Care for Obesity and Psoriatic Disease
- Medac - New insights into first-line conventional therapies in RA
- Novartis - Shifting Sands in Sjögren’s: Targeting the Disease Activity Beneath the Surface
- UCB - Mind the Remission GAP in SpA: When Symptoms Say “Fine” but Inflammation Says “Not Yet”
17:30 – 18:45 BST
- Argenx - “Guess Who?”: Revealing autoantibodies as hidden drivers of autoimmune rheumatic diseases
- Biogen - The Evolution of Lupus: Progress, Persistent Burden, and What Comes Next
- Cabaletta Bio - Recent Advances in CAR T Cell Therapy for Autoimmune Diseases
- CSL - Evolving strategies in ANCA-associated vasculitis (GPA/MPA): From clinical trials to real-world practice
- GSK - VEXAS Syndrome: Multidisciplinary Expert Perspectives on Strategies for Patient Care
- Novartis - Translating Evidence into Practice: Achieving Treatment Success in PsA and axSpA Clinics
- Sanofi - Practical Implications of Evolving Real-World Evidence and Polymyalgia Rheumatica Guidelines
- Viatris - Advances in understanding SLE: From pathophysiology to future precision care
09:45 – 10:15 BST
- AbbVie - Personalized paths to glucocorticoid-free remission in giant cell arteritis
- Alexion, AstraZeneca Rare Disease - An Overview of Hypophosphatasia (HPP)
- Novartis - Treat-to-target in FMF: Challenging subclinical inflammation
16:15 – 16:45 BST
- Boehringer Ingelheim - Screen, monitor and manage CTD-ILD: practical application of ERS/EULAR guidelines and expert insights
- GSK - Could this be Lupus? Identifying Atypical SLE Manifestations in End-Stage Organ Systems
- UCB - Treating WoCBA with SLE: Are We Flying Blind?
08:15 - 09:30 (75 mins) | Satellite Symposia |
| 09:30 | Exhibition opens |
09:30 - 10:30 (60 mins) 09:45 - 10:15 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
10:30 - 12:00 (90 mins) | Abstract sessions |
12:00 - 13:30 (90 mins) | Lunch & Poster Viewing and Tours |
13:30 - 14:45 (75 mins) | Scientific sessions |
14:45 - 15:45 (60 mins) 15:00 - 15:30 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
| 15:45 - 17:00 (75 mins) | Scientific sessions |
| 17:00 | Exhibition Closes |
| 17:30 - 18:45 (75 mins) | Satellite Symposia |
12:15 – 13:30 BST
- AbbVie - Improving care in spondyloarthritis: A multidisciplinary approach to the disease and its extra-musculoskeletal manifestations
- AbbVie - Achieving early and accurate diagnosis of axial spondyloarthritis: A case-based discussion
- Amgen - Targeting CD19+ B-Cells in IgG4-Related Disease: Clinical Evidence and Implications for Long-Term Management
- Boehringer Ingelheim - New dimensions in systemic sclerosis: evolving concepts in diagnosis, prognosis and intervention
- GSK - Beyond the flare: Acting early in SLE and LN to prevent long-term damage
- Merck - Under the surface: new perspectives in lupus with TLR7/8 inhibition
- Novartis - The Grand SpA Debate: Should we target pain or inflammation?
- UCB - Fire and Fragility: The Hidden Bone Burden and Rheumatoid Arthritis
17:30 – 18:45 BST
- GSK - Advancing EGPA care: From Timely Recognition to Intervention
- Kyowa Kirin - Shift the trajectory: Why rheumatology management for rare bone diseases, such as XLH, must change
- Vor Bio - Upstream Targeting of B Cell Dysregulation to Address the Pathology of Primary Sjögren Disease
09:45 – 10:15 BST
AstraZeneca - The benefit of collaboration in SLE: acting early in rheumatology & dermatology
Eli Lilly - Obesity in Psoriatic Arthritis: Mechanisms, Misconceptions, and Management
GSK - EGPA in Focus: What’s Improved, What’s Missing, What’s Next?
16:15 – 16:45 BST
Alexion, AstraZeneca Rare Disease - Could It Be Hypophosphatasia (HPP)? A Conversation with the Expert
GSK - Preventing Progression in Lupus: Are You Intervening Early Enough?
08:15 - 09:30 (75 mins) | Satellite Symposia |
| 09:30 | Exhibition opens |
09:30 - 10:30 (60 mins) 09:45 - 10:15 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
10:30 - 12:00 (90 mins) | Abstract sessions |
12:00 - 13:30 (90 mins) | Lunch & Poster Viewing and Tours |
13:30 - 14:45 (75 mins) | Scientific sessions |
14:45 - 15:45 (60 mins) 15:00 - 15:30 (30 mins) | Coffee Break / Exhibition Visit / Poster Viewing and Tours Meet the EULAR Expert / Consult the Expert |
| 15:45 - 17:00 (75 mins) | Scientific sessions |
| 17:00 | Exhibition Closes |
| 17:30 - 18:45 (75 mins) | Satellite Symposia |
| 09:00 | Exhibition opens |
| 09:00 - 10:15 (75 mins) | Scientific sessions |
| 10:15 - 12:00 (105 mins) | Coffee Break / Exhibition Visit |
| 10:15 - 11:45 (90 mins) | Poster Viewing and Tours |
| 12:00 - 13:15 (75 mins) | Scientific sessions |
| 13:15 - 14:45 (90 mins) | Highlights session |
| 14:30 | Exhibition closes |